The symposium will provide a broad overview on the diversity of portal hypertension in the Western World and in the Asia Pacific Region. Experts will discuss the presentation, diagnosis, and management of the consequences of portal hypertension, and will benefit all health care professionals engaged in encountering these patients in their clinical practice.K. Rajender Reddy Florence Wong Florence Wong, MD is a full professor at the University of Toronto and staff Hepatologist at the Toronto General Hospital, Ontario, Canada.

Estella M. Alonso, Simon P. Horslen, Edward M. Behrens, Edward Doo – 14 November 2016 – Pediatric acute liver failure (PALF) is a potentially devastating condition that occurs in previously healthy children of all ages and frequently leads to a rapid clinical deterioration. An identified cause for liver injury is lacking in approximately 30% of cases. Children with undetermined diagnosis have lower spontaneous survival and higher rates of transplantation and death than other diagnostic groups.

Micol Ravà, Aleco D'Andrea, Mirko Doni, Theresia R. Kress, Renato Ostuni, Valerio Bianchi, Marco J. Morelli, Agnese Collino, Serena Ghisletti, Paola Nicoli, Camilla Recordati, Maria Iascone, Aurelio Sonzogni, Lorenzo D'Antiga, Ruchi Shukla, Geoffrey J. Faulkner, Gioacchino Natoli, Stefano Campaner, Bruno Amati – 14 November 2016 – The ST18 gene has been proposed to act either as a tumor suppressor or as an oncogene in different human cancers, but direct evidence for its role in tumorigenesis has been lacking thus far.

Elizabeth P. Newberry, Yan Xie, Susan M. Kennedy, Mark J. Graham, Rosanne M. Crooke, Hui Jiang, Anping Chen, Daniel S. Ory, Nicholas O. Davidson – 14 November 2016 – Blocking hepatic very low‐density lipoprotein secretion through genetic or pharmacologic inhibition of microsomal triglyceride transfer protein (Mttp) causes hepatic steatosis, yet the risks for developing hepatic fibrosis are poorly understood. We report that liver‐specific Mttp knockout mice (Mttp‐LKO) exhibit both steatosis and fibrosis, which is exacerbated by a high‐transfat/fructose diet.

This workshop will focus on how inducible pluripotent stem cells (iPSCs) can be used to produce liver cells and organoids. These are exciting new tools for experimental hepatology and hold great promise for clinical hepatology. The generation of iPSC-derived liver cells enables studies of the pathophysiology of several human conditions and to explore the effects of new drugs and treatment following a personalized medicine approach.

The main objective of this program is to educate medical students or residents who are considering a career in hepatology about training opportunities as well as arm the current GI and/or hepatology fellows with knowledge to help them succeed in academic hepatology. Time will be decidated specifically to discussion of clinical and basic science research, funding mechanisms, mentorship and important career crossroads. An overview of the responsibilities and opportunities of an academic hepatologist and clinician educator will all be provided.

As the practice of hepatology has matured over the past decade many AASLD members have successfully developed or transitioned to community-based hepatology practices in one of three major areas: a community based health care system, a multi-speciality group practice or a hepatology-only medical practice.

This program will address the various designs used in patient-oriented research, including the strengths and limitations to each approach as well as the impact each technique has had on the study and care of patients with liver disease. In addition, approaches to obtaining funding for such research, as well as the development and use of quality measures for the care of patients with chronic liver disease will be discussed.

This program is intended to explore current and novel health care delivery approaches and strategies for managing populations affected by cirrhosis and portal hypertension. In contrast to disease-based symposium focused on novel diagnostic and treatment approaches, this program intends to focus on current and evolving approaches inspired by delivery system reform to ensure that high quality, patient-centered, and resource efficien medical care is delivered to large segments of patients with advanced liver disease. The emphasis of this program is on clinical knowledge.Michael Volk Brett E.

Colleen N. Feriod, Andre Gustavo Oliveira, Mateus T. Guerra, Lily Nguyen, Kisha Mitchell Richards, Michael J. Jurczak, Hai‐Bin Ruan, Joao Paulo Camporez, Xiaoyong Yang, Gerald I. Shulman, Anton M. Bennett, Michael H. Nathanson, Barbara E. Ehrlich – 11 November 2016 – Fatty liver is the most common type of liver disease, affecting nearly one third of the U.S. population and more than half a billion people worldwide. Abnormalities in endoplasmic reticulum (ER) calcium handling and mitochondrial function each have been implicated in abnormal lipid droplet formation.